Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer release_atpscscfbbhonhwq3kufd4zrti

by Daria Handkiewicz-Junak, Tomasz Gawlik, Jozef Rozkosz, Zbigniew Puch, Barbara Michalik, Elżbieta Gubala, Jolanta Krajewska, Aneta Kluczewska, Barbara Jarzab

Published in European Journal of Endocrinology by Bioscientifica.

2015   Volume 173, p873-881

Abstract

<jats:sec><jats:title>Aim</jats:title>Although recombinant human thyrotropin (rhTSH) is widely used in treating differentiated thyroid cancer (DTC), almost all clinical investigation has been in adults. The aim of our retrospective study was to evaluate outcomes of adjuvant, rhTSH-aided radioiodine treatment in children/adolescents with DTC and to compare them to <jats:sup>131</jats:sup>I therapy during <jats:sc>l</jats:sc>-thyroxin withdrawal (THW).</jats:sec><jats:sec><jats:title>Methods</jats:title>Patients with the diagnosis of DTC who were ≤18 years of age and had no signs of persistent disease at the time of <jats:sup>131</jats:sup>I treatment were included; 48 patients were treated after rhTSH (rhTSH group) and 82 after THW group. The median time of follow-up after therapy was 67 months and was longer in the THW group (99 vs 43 months, <jats:italic>P</jats:italic>&lt;0.05).</jats:sec><jats:sec><jats:title>Results</jats:title>On the day of <jats:sup>131</jats:sup>I administration, all but one patient had TSH levels above 25 μIU/ml. Peak TSH concentration was significantly higher in the rhTSH group (152 μIU/ml vs 91 μIU/ml). Similarly, the thyroglobulin concentration was higher in the rhTSH group (9.7 ng/ml vs 1.8 ng/ml). No side effects requiring medical intervention were recorded after rhTSH administration. The evaluation of disease outcomes during TSH stimulation (6–18 months after <jats:sup>131</jats:sup>I treatment) revealed equal rates of thyroid ablation (71%) in both groups. During subsequent follow-up, five patients showed recurrence (<jats:italic>P</jats:italic>&gt;0.05).</jats:sec><jats:sec><jats:title>Conclusions</jats:title>In children/adolescents, rhTSH-aided adjuvant radioiodine treatment is associated with rates of remnant ablation and short-term recurrence similar to THW. As this preparation has several advantages over THW, rhTSH may become the preferred method of TSH stimulation once studies of long-term outcomes show non-inferiority to THW in this age group.</jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf  236.2 kB
file_owy6uxcpsnfvrgyhtg5hh22gdq
web.archive.org (webarchive)
www.eje-online.org (web)
application/pdf  257.9 kB
file_sui6vfb2djcfvjk4hqajxamvme
web.archive.org (webarchive)
eje.bioscientifica.com (web)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Year   2015
DOI  10.1530/eje-15-0562
PubMed  26423095
Journal Metadata
Not in DOAJ
In Keepers Registry
ISSN-L:  0804-4643
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: d12e293e-5dc8-4d70-843c-43b37988cc41
API URL: JSON